Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KB 707

Next Previous
X
Search
Drug Profile

KB 707

Alternative Names: KB-707

Latest Information Update: 08 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Krystal Biotech
  • Class Antineoplastics; Gene therapies; Immunotherapies
  • Mechanism of Action Gene transference; Immunologic cytotoxicity; Interleukin 12 replacements; Interleukin 2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Lung cancer; Solid tumours

Most Recent Events

  • 05 Aug 2024 US FDA approves Rare Pediatric Disease Designation for osteosarcoma
  • 13 Feb 2024 KB 707 receives Fast Track designation for Lung cancer [Inhalation,Aerosol] (Late-stage disease, Monotherapy, Second-line therapy or greater) in USA
  • 31 Jan 2024 The FDA clears an amendment to the Krystal Biotech's previously cleared investigational new drug (IND) application allowing for the evaluation of inhaled KB 707 for Lung cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top